First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases.
Entero Therapeutics stock last closed at $0.35, down 6.35% from the previous day, and has decreased 87.84% in one year. It has underperformed other stocks in the Biotechnology industry by 0.1 percentage points. Entero Therapeutics stock is currently +91.35% from its 52-week low of $0.19, and -89.59% from its 52-week high of $3.40.
There are currently 4.77M ENTO shares outstanding. The market capitalization of ENTO is $1.69M. In the past 24 hours, 87,799 ENTO shares were traded.
You need an online brokerage account in order to access the NASDAQ market and buy ENTO shares.
Based on our analysis, eToro is the best place to buy stocks. eToro gives you:
Get $10 towards your purchase of stock by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've selected the right brokerage, you need to fill out some personal details so you are able to buy ENTO today.
Now that you have finished signing up on the best stock trading app, your next step is to transfer the money for your investment:
Check out the walkthrough below if you need help transferring money into your new investment account.
Once you have selected the best place to buy Entero Therapeutics stock, it's absolutely critical to evaluate their stock prior to investing, so you can understand the risk and upside.
WallStreetZen was designed to help everyday investors perform better fundamental analysis in less time.
You can see all of the due diligence checks on ENTO's stock page.
Investors use a variety of different financial metrics, analyses, models, and charts to gauge ENTO's fair value.
You can do more valuation analysis on ENTO's stock here.
You can dive deeper into what analysts are forecasting on the Entero Therapeutics stock forecast page.
Over the last 12 months, executives and large shareholders at ENTO have sold more shares than they have bought.
Sarah Romano, Chief Financial Officer of ENTO, was the latest ENTO insider to sell. They sold $465.28 worth of ENTO shares on Jan 6, 2025.
Dig into more about who owns ENTO shares here.
No, Entero Therapeutics doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
There are two main order types:
Press the Open Trade button and eToro will execute the order.
If you need additional help with buying stocks on eToro, click the how to video below:
Now that you own some ENTO shares, you'll want to keep up with your investment.
Add ENTO to a watchlist to track your ENTO stock.
To summarize, here are the 6 steps for buying Entero Therapeutics stock:
If you need a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get the latest scoop on your investment in Entero Therapeutics, create a watchlist today.